Gylden Pharma Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$34.9M
- Investors
-
5
Gylden Pharma General Information
Description
Developer of set-point vaccines designed to fight against viral and bacterial infectious diseases. The company's vaccines create synthetic non-biological components that prime immune cells that can destroy pathogen-infected cells for diseases that include dengue fever, Zika, Ebola, and pandemic flu, as well as serious intracellular bacterial infections, enabling healthcare professionals to prevent the acute or severe manifestation of the disease.
Contact Information
Website
www.gyldenpharma.comCorporate Office
- 4/5 Dunmore Court
- Wootton Road
- Abingdon OX13 6BH
- England, United Kingdom
Corporate Office
- 4/5 Dunmore Court
- Wootton Road
- Abingdon OX13 6BH
- England, United Kingdom
Gylden Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A) | 10-Jan-2022 | $34.9M | Completed | Clinical Trials - Phase 1 | ||
| 5. Early Stage VC | 15-Nov-2019 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 14-May-2018 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 07-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 05-Apr-2017 | $619K | $89.2K | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 07-Jun-2016 | $89.2K | $89.2K | Completed | Startup |
Gylden Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A Preference | ||||||||
| Series A Preference | ||||||||
| Preference | ||||||||
| Ordinary | ||||||||
| Preference | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Series A Preference | 1,840,658 | $0.000003 | $6.24 | $6.24 | 1x | $6.24 | 9.37% | |
| Ordinary | 404,464 | $0.000003 | $6.24 | $6.24 | 1x | $6.24 | 2.06% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Gylden Pharma Comparisons
Industry
Financing
Details
Gylden Pharma Competitors (2)
One of Gylden Pharma’s 2 competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA | ||||
| XBiotech | Corporation | Austin, TX |
Gylden Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Gylden Pharma Patents
Gylden Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240269264-A1 | Human coronavirus 229e derived peptides | Inactive | 02-Jun-2021 | ||
| WO-2022253917-A1 | Human coronavirus 229e derived peptides | Inactive | 02-Jun-2021 | ||
| US-20250101065-A1 | Reverse peptides from coronavirus for immunogenic purposes | Pending | 02-Jun-2021 | ||
| GB-202104095-D0 | Superantigen peptides | Inactive | 24-Mar-2021 | ||
| EP-4294435-A1 | Reverse peptides from coronavirus for immunogenic purposes | Pending | 16-Feb-2021 | C07K14/005 |
Gylden Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Gylden Pharma Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cell Rising Capital | Venture Capital | Minority | ||
| Maiora Ventures | Venture Capital | Minority | ||
| TAD Tech | Venture Capital | Minority | ||
| Vickers Venture Partners | Corporate Venture Capital | Minority | ||
| Innovate UK | Government |
Gylden Pharma Acquisitions (2)
Gylden Pharma’s most recent deal was a Merger/Acquisition with Zosano Pharma for . The deal was made on 25-Aug-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zosano Pharma | 25-Aug-2022 | Merger/Acquisition | Drug Delivery | ||
| ImmProNano | 01-Sep-2020 | Merger/Acquisition | Drug Discovery |
Gylden Pharma FAQs
-
When was Gylden Pharma founded?
Gylden Pharma was founded in 2016.
-
Where is Gylden Pharma headquartered?
Gylden Pharma is headquartered in Abingdon, United Kingdom.
-
What is the size of Gylden Pharma?
Gylden Pharma has 36 total employees.
-
What industry is Gylden Pharma in?
Gylden Pharma’s primary industry is Drug Discovery.
-
Is Gylden Pharma a private or public company?
Gylden Pharma is a Private company.
-
What is the current valuation of Gylden Pharma?
The current valuation of Gylden Pharma is .
-
What is Gylden Pharma’s current revenue?
The current revenue for Gylden Pharma is .
-
How much funding has Gylden Pharma raised over time?
Gylden Pharma has raised $53.5M.
-
Who are Gylden Pharma’s investors?
Cell Rising Capital, Maiora Ventures, TAD Tech, Vickers Venture Partners, and Innovate UK have invested in Gylden Pharma.
-
Who are Gylden Pharma’s competitors?
CytoAgents and XBiotech are competitors of Gylden Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
